Revelation Biosciences (NASDAQ:REVB) Stock Price Up 1.4% – Here’s What Happened

Posted by Francis Steltz on Sep 3rd, 2026

Revelation Biosciences, Inc. (NASDAQ:REVB – Get Free Report) shares rose 1.4% on Wednesday . The company traded as high as $1.04 and last traded at $1.00. 17,999 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 42,725 shares. The stock had previously closed at $0.9866.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, August 25th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on REVB

Revelation Biosciences Stock Up 1.4%

The firm has a market capitalization of $3.98 million, a price-to-earnings ratio of -0.08 and a beta of -0.14. The stock’s 50 day moving average price is $1.06 and its two-hundred day moving average price is $1.12.

Revelation Biosciences (NASDAQ:REVB – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.01. On average, equities analysts expect that Revelation Biosciences, Inc. will post -5.18 EPS for the current fiscal year.

Institutional Investors Weigh In On Revelation Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in REVB. Armistice Capital LLC grew its stake in shares of Revelation Biosciences by 442.8% in the 4th quarter. Armistice Capital LLC now owns 434,272 shares of the company’s stock valued at $347,000 after buying an additional 354,272 shares in the last quarter. Geode Capital Management LLC acquired a new position in Revelation Biosciences in the fourth quarter worth approximately $27,000. Finally, Sabby Management LLC increased its holdings in Revelation Biosciences by 192.5% in the fourth quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock worth $484,000 after buying an additional 398,651 shares during the last quarter. 12.80% of the stock is owned by hedge funds and other institutional investors.

About Revelation Biosciences

(Get Free Report)

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.